NO LEGACY effect. Why these results are different from previous trials? @askrenal Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/N7NJwMyL7U
2型糖尿病患者の中央値5.6年の強化血糖コントロールは、15年間にわたって、標準治療と比較して主要心血管イベントや死亡リスクは低下しなかった。 https://t.co/mdxkTKKXU0
“There was no evidence of a legacy effect or a mortality benefit with intensive glucose control.”
Unlike DM1 (DCCT) and new onset DM2 (UKPDS), VADT with long-standing DM2 show no legacy effect of glucose lowering on CVD and death over 15 years of follow up. Not totally surprising due to competing risks but highlights the diff between DM1 and DM2.
RT @hmbaquero: Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/RE1uOC0cao
Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/RE1uOC0cao
RT @rafabravo: Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/Z1dPw9r0jW
RT @ggimenezendocri: https://t.co/j08q1Du1iD Guidance Statement 2: Clinicians should aim to achieve an HbA1c level between 7% and 8% in mos…
RT @rafabravo: Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/Z1dPw9r0jW
Looks like the glucose monitoring device sector will take a hit, Intensive Glucose monitoring unnecessary. #diabetes #diabetesireland Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/gdBiEXEvY6
RT @joaqmorera: Pues aunque se iguale el riesgo de evento cardiovascular a largo plazo (15a) al menos un control intensivo de la diabetes l…
Pues aunque se iguale el riesgo de evento cardiovascular a largo plazo (15a) al menos un control intensivo de la diabetes lo disminuye en los primeros 5-6 años. Algo merecerá la pena
RT @ggimenezendocri: https://t.co/j08q1Du1iD Guidance Statement 2: Clinicians should aim to achieve an HbA1c level between 7% and 8% in mos…
Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/Z1dPw9r0jW
Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/mWFohyM9rw
RT @Dr_Khan: Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up https://t.co/eVeqHbWYeM /via @NEJM
Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up https://t.co/eVeqHbWYeM /via @NEJM
RT @NEJM: The VADT follow-up study was designed to examine long-term consequences of intensive glycemic control on cardiovascular disease o…
RT @florencarral: Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/XaXCQ3XdI8
RT @NEJM: The VADT follow-up study was designed to examine long-term consequences of intensive glycemic control on cardiovascular disease o…
RT @ggimenezendocri: https://t.co/j08q1Du1iD Guidance Statement 2: Clinicians should aim to achieve an HbA1c level between 7% and 8% in mos…
RT @NEJM: The VADT follow-up study was designed to examine long-term consequences of intensive glycemic control on cardiovascular disease o…
RT @ggimenezendocri: https://t.co/j08q1Du1iD Guidance Statement 2: Clinicians should aim to achieve an HbA1c level between 7% and 8% in mos…
RT @NEJM: The VADT follow-up study was designed to examine long-term consequences of intensive glycemic control on cardiovascular disease o…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
Diabetes: aos 15 anos de follow up do VADT: controlo intensivo de glucose não está associado a menor taxa de eventos cardiovasculares que o tratamento habitual. Contraria DCCT e UKPDS e concorda com ACCORD e ADVANCE https://t.co/IxhIdfIWLg #observacional
RT @CristobMorales: https://t.co/L0mYl4aCQs T2DM with intensive glucose control for 5.6 years had a lower risk of CV events than those who…
RT @FZores: et je vous le donne en mille : aucun effet à 15 ans du contrôle strict de la glycémie. Nada. Pas de mémoire glycémique. Je vou…
RT @CristobMorales: https://t.co/L0mYl4aCQs T2DM with intensive glucose control for 5.6 years had a lower risk of CV events than those who…
Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | The New England Journal of Medicine https://t.co/B0xLwdd5So
RT @NEJM: The VADT follow-up study was designed to examine long-term consequences of intensive glycemic control on cardiovascular disease o…
RT @NEJM: The VADT follow-up study was designed to examine long-term consequences of intensive glycemic control on cardiovascular disease o…
RT @NEJM: The VADT follow-up study was designed to examine long-term consequences of intensive glycemic control on cardiovascular disease o…
RT @NEJM: The VADT follow-up study was designed to examine long-term consequences of intensive glycemic control on cardiovascular disease o…
RT @NEJM: The VADT follow-up study was designed to examine long-term consequences of intensive glycemic control on cardiovascular disease o…
RT @NEJM: The VADT follow-up study was designed to examine long-term consequences of intensive glycemic control on cardiovascular disease o…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
RT @CristobMorales: https://t.co/L0mYl4aCQs T2DM with intensive glucose control for 5.6 years had a lower risk of CV events than those who…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
RT @drjohnmorley: Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/UbfqXKg6EA
RT @NEJM: The VADT follow-up study was designed to examine long-term consequences of intensive glycemic control on cardiovascular disease o…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
RT @NEJM: The VADT follow-up study was designed to examine long-term consequences of intensive glycemic control on cardiovascular disease o…
RT @CristobMorales: https://t.co/L0mYl4aCQs T2DM with intensive glucose control for 5.6 years had a lower risk of CV events than those who…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
https://t.co/j08q1Du1iD Guidance Statement 2: Clinicians should aim to achieve an HbA1c level between 7% and 8% in most patients with type 2 #diabetes in occordance with VADT results? https://t.co/Y6GokogMXl …
Latest from NEJM https://t.co/1vEYAoa3Fs Maybe time to try dietary measures as well as intensive therapies to reduce HbA1c levels Cholesterol profile of participants (n= 1655) is interesting also. (last sentence in left graphic ends '..... 15 years was n
RT @CristobMorales: https://t.co/L0mYl4aCQs T2DM with intensive glucose control for 5.6 years had a lower risk of CV events than those who…
La glicada no es todo pero sí tiene poder ...
https://t.co/esCEJdscUd … T2DM with intensive glucose control for 5.6 years had a lower risk of CV events than those who received standard therapy only during the prolonged period in which the A1c curves were separated. There was no evidence of a legacy… h
RT @ggimenezendocri: Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/Y6GokogMXl A major…
RT @CristobMorales: https://t.co/L0mYl4aCQs T2DM with intensive glucose control for 5.6 years had a lower risk of CV events than those who…
RT @FZores: et je vous le donne en mille : aucun effet à 15 ans du contrôle strict de la glycémie. Nada. Pas de mémoire glycémique. Je vou…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up. 2型糖尿病患者における強化血糖コントロール ― 15年間の追跡調査 P.D. Reaven and Others. N Engl J Med 2019; 380:2215-2224 https://t.co/JUcEyVcn9A
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
RT @CristobMorales: https://t.co/L0mYl4aCQs T2DM with intensive glucose control for 5.6 years had a lower risk of CV events than those who…
No legacy effect on CVD outcomes for intensive glucose control in diabetes
RT @drjohnmorley: Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/UbfqXKg6EA
RT @CristobMorales: https://t.co/L0mYl4aCQs T2DM with intensive glucose control for 5.6 years had a lower risk of CV events than those who…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
RT @ariosvaca: Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/K23VQUbuwS
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
RT @hmkyale: 15 years of follow-up and this VA study still shows that even good surrogate endpoints don’t tell the whole story and you need…
RT @hmkyale: 15 years of follow-up and this VA study still shows that even good surrogate endpoints don’t tell the whole story and you need…
Important 15 year study of glycemic legacy effects from the VA. https://t.co/Xnnb73LP1A how to reconcile older and newer data? Nice editorial by @nedalai @NEJM #diabetes #EndoTwitter #ADA2019 https://t.co/FFC49mGmuw
RT @CristobMorales: https://t.co/L0mYl4aCQs T2DM with intensive glucose control for 5.6 years had a lower risk of CV events than those who…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
et je vous le donne en mille : aucun effet à 15 ans du contrôle strict de la glycémie. Nada. Pas de mémoire glycémique. Je vous laisse lire l'édito qui va avec dont je vous donne les derniers paragraphes 3/4 https://t.co/Zj8qljABEb https://t.co/nLjc4TRrPt
平均5.6年間、集中的な血糖コントロール治療にランダムに割り当てられた2型糖尿病の参加者は、糖化ヘモグロビン曲線が改善した期間のみ標準治療を受けた人より心血管イベントのリスクが低かった。しかし、この差は介入期間の3年後にはほぼなくなった。 #糖尿病 https://t.co/DaM44Nh7yi
RT @NEJM: The VADT follow-up study was designed to examine long-term consequences of intensive glycemic control on cardiovascular disease o…
RT @Office_j: 【厳格血糖管理のレガシー効果確認されず:VADT 15年観察/ NEJM】 2型DM 1791例、5.6年 [中央値] ランダム化、計13.6年 [中央値] 観察:ランダム化期間中HbA1c「<6%」目標群で、「<9%」群に比べ、死亡・CVイベント…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
RT @hmkyale: 15 years of follow-up and this VA study still shows that even good surrogate endpoints don’t tell the whole story and you need…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
RT @NEJM: The VADT follow-up study was designed to examine long-term consequences of intensive glycemic control on cardiovascular disease o…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
RT @CristobMorales: https://t.co/L0mYl4aCQs T2DM with intensive glucose control for 5.6 years had a lower risk of CV events than those who…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/UbfqXKg6EA
Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/OKlBlZI55v
Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/brzkn4BDgO
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/QPbSkwlTQG
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
RT @mencardio: Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/ODW0fR8lWT @ivanovich13 @…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/YsLpJdDkcP
RT @hmkyale: 15 years of follow-up and this VA study still shows that even good surrogate endpoints don’t tell the whole story and you need…
RT @florencarral: Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/XaXCQ3XdI8
RT @NEJM: The VADT follow-up study was designed to examine long-term consequences of intensive glycemic control on cardiovascular disease o…
Intensive Glucose Control in Patients with Type 2 Diabetes — 15-Year Follow-up | NEJM https://t.co/K23VQUbuwS
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…
RT @davidludwigmd: Among a large group of veterans with type 2 diabetes, the cardiovascular benefit of intensive drug treatment did not per…